• Success with pre-Clinical Milestone triggers Payment
    Alastair Smith

News & Views

Success with pre-Clinical Milestone triggers Payment

Oct 15 2021

Clinical stage biopharmaceutical Avacta Group has announced achievement of a pre-clinical milestone in its multi-target therapeutics development partnership (ILM No, 2020) with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, resulting in an undisclosed milestone payment.

 The agreement allows LG Chem development rights on a world-wide basis of Avacta’s Affimer® PD-L1 inhibitor with Affimer XT® serum half-life extension, along with some other biotherapeutics combined with Affimer XT® half-life extension for a range of indications.

LG Chem has successfully completed certain pre-clinical in-vivo models in the PD-L1/XT programme leading to the selection of a pre-clinical candidate for further development towards the clinic which triggered the payment.

 Dr. Alastair Smith, Chief Executive of Avacta Group, commented: “I am delighted with the progress in our important strategic partnership with LG Chem. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative drugs.

 “I am particularly pleased that we have achieved this significant milestone with a novel Affimer® bispecific product, which highlights the tremendous promise of the Affimer® platform.”

More information online

Digital Edition

Lab Asia April 2022

April 2022

In This Edition Chromatography - Achiral Supercritical Fluid Chromatography (SFC) for the Purification of Pharmaceuticals - Equivalent GC systems performance for regulatory method compliance...

View all digital editions


GCxGC Symposium

May 29 2022 Virtual event

Chemspec Europe

May 31 2022 Frankfurt, Germany

ASMS Conference

Jun 05 2022 Minneapolis, MN, USA


Jun 08 2022 Rotterdam, Netherlands

ChemBio Finland 2022 - NEW DATES

Jun 08 2022 Helsinki, Finland

View all events